AKT1 and Hepatic fibrosis: Recently, the dual AdipoR1/AdipoR2-based agonist JT003 has been demonstrated to enhance fatty acid oxidation and glucose uptake and mitigate liver fibrosis and insulin resistance in mice via signaling pathways, including AMPK, PPARα, and AKT [44].